Patents by Inventor Nagasree Chakka

Nagasree Chakka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ARYL OR HETEROARYL DERIVATIVE
    Publication number: 20230167073
    Abstract: A compound indicated by formula (I) or a pharmacologically acceptable salt thereof is provided as a compound that can be a therapeutic or prophylactic drug for TRPC6-related diseases, such as nephrotic syndrome, membranous nephropathy, acute renal failure, septicemia, chronic renal failure, diabetic nephropathy, pulmonary hypertension, acute lung injury, heart failure, malignant tumor, and muscular dystrophy. (In the formula, Ar1, Ar2, X1-X3, R1, R3, R7, R8, L1, and L2 are as defined in the specifications.
    Type: Application
    Filed: April 15, 2021
    Publication date: June 1, 2023
    Applicant: Teijin Pharma Limited
    Inventors: Sakae SUGIYAMA, Takuya YOKOSAKA, Kunio MINAMIZONO, Asahi KAWANA, Toshiyuki KANEKO, Akinobu MARUYAMA, Kosuke SASAKI, Shinnosuke HOSODA, Masaki KOSHIMIZU, Susumu TAKEUCHI, Kenta KATO, Nagasree CHAKKA, Brett M. JOHNSON, Ryan D. WHITE, Wei ZHAO
  • BENZIMIDAZOLE DERIVATIVES AND THEIR USES
    Publication number: 20220204477
    Abstract: The present invention provides compounds which inhibit the activity of TRPC6, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Application
    Filed: April 10, 2020
    Publication date: June 30, 2022
    Applicant: Teijin Pharma Limited
    Inventors: Nagasree CHAKKA, Hua GAO, Angel GUZMAN-PEREZ, Brett Michael JOHNSON, Madeleine KIEFFER, Justin MALINOWSKI, Laurie SCHENKEL
  • Benzimidazole derivatives and their uses
    Patent number: 11332459
    Abstract: The present invention relates to inhibitors of Transient Receptor Potential Channel 6 (TRPC6) protein activity. The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: May 17, 2022
    Assignee: TEIJIN PHARMA LIMITED
    Inventors: Michael D. Bartberger, Nagasree Chakka, Hua Gao, Angel Guzman-Perez, Daniel B. Horne, Zihao Hua, Madeleine Kieffer, Daniel C. H. Lin, Benjamin Charles Milgram, Jane Panteleev, Laurie Schenkel, John Stellwagen, Matthew Weiss, Ryan D. White, Wei Zhao
  • BENZIMIDAZOLE DERIVATIVES AND THEIR USES
    Publication number: 20200308145
    Abstract: The present invention relates to inhibitors of Transient Receptor Potential Channel 6 (TRPC6) protein activity. The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Application
    Filed: October 18, 2018
    Publication date: October 1, 2020
    Applicant: Amgen Inc.
    Inventors: Michael D. BARTBERGER, Nagasree CHAKKA, Hua GAO, Angel GUZMAN-PEREZ, Daniel B. HORNE, Zihao HUA, Madeleine KIEFFER, Daniel C. H. Lin, Benjamin Charles MILGRAM, Jane PANTELEEV, Laurie SCHENKEL, John STELLWAGEN, Matthew WEISS, Ryan D. WHITE, Wei ZHAO
  • Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
    Patent number: 9663508
    Abstract: The present invention provides compounds of Formula (Ia), and pharmaceutically acceptable salts thereof. The compounds are useful as inhibitors of voltage-gated sodium channels, in particular Nav 1.7. as described in the specification. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention, as well as intermediates and processes useful for making the compounds.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: May 30, 2017
    Assignee: Amgen Inc.
    Inventors: Howard Bregman, Nagasree Chakka, Erin F. Dimauro, Hua Gao, Hakan Gunaydin, Hongbing Huang, Philip R. Olivieri, Laurie Schenkel, Matthew Weiss
  • SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS
    Publication number: 20170114075
    Abstract: This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
    Type: Application
    Filed: August 31, 2016
    Publication date: April 27, 2017
    Inventors: Mikhail Chafeev, Sultan Chowdhury, Lauren Fraser, Jianmin Fu, Jonathan Langille, Shifeng Liu, Jianyu Sun, Shaoyi Sun, Serguei Sviridov, Mark Wood, Alla Yurevna Zenova, Qi Jia, Jean-Jacques Alexandre Cadieux, Simon J. Gauthier, Amy Frances Douglas, Tom Hsieh, Nagasree Chakka, Zoran Cikojevic
  • Quinazolinone compounds and derivatives thereof
    Patent number: 9505749
    Abstract: Compounds of Formula I are useful inhibitors of tankyrase. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: August 27, 2013
    Date of Patent: November 29, 2016
    Assignee: AMGEN INC.
    Inventors: Howard Bregman, John L. Buchanan, Nagasree Chakka, Erin F. Dimauro, Hakan Gunaydin, Angel Guzman-Perez, Zihao Hua, Xin Huang
  • Spiro-oxindole compounds and their use as therapeutic agents
    Patent number: 9458178
    Abstract: This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: October 4, 2016
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Mikhail Chafeev, Sultan Chowdhury, Lauren Fraser, Jianmin Fu, Jonathan Langille, Shifeng Liu, Jianyu Sun, Shaoyi Sun, Serguei Sviridov, Mark Wood, Alla Yurevna Zenova, Qi Jia, Jean-Jacques Alexandre Cadieux, Simon J. Gauthier, Amy Frances Douglas, Tom Hsieh, Nagasree Chakka, Zoran Cikojevic
  • Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors
    Publication number: 20160214971
    Abstract: The present invention provides compounds of Formula (Ia), and pharmaceutically acceptable salts thereof. The compounds are useful as inhibitors of voltage-gated sodium channels, in particular Nav 1.7. as described in the specification. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention, as well as intermediates and processes useful for making the compounds.
    Type: Application
    Filed: October 1, 2014
    Publication date: July 28, 2016
    Applicant: One Amgen Center Drive
    Inventors: Howard BERGMAN, Nagasree CHAKKA, Erin F. DIMAURO, Hau GAO, Hakan GUNAYDIN, Homgbing HUANG, Philip R. OLIVIERI, Laurie SCHENKEL, Matthew WEISS
  • N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
    Publication number: 20160175315
    Abstract: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing N-piperidinyl acetamide derivatives as shown in formula (1).
    Type: Application
    Filed: June 29, 2015
    Publication date: June 23, 2016
    Inventors: Hassan PAJOUHESH, Ramesh KAUL, Yanbing DING, Yongbao ZHU, Lingyun ZHANG, Nagasree CHAKKA, Michael Edward GRIMWOOD, Jason TAN, Yuanxi ZHOU
  • Pyrazole amide derivative
    Patent number: 9365522
    Abstract: The present invention relates to a novel compound having a function of inhibiting ROR? activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: June 14, 2016
    Assignees: AMGEN INC., TEIJIN PHARMA LIMITED
    Inventors: Hilary Plake Beck, Shon Keith Booker, Howard Bregman, Victor J. Cee, Nagasree Chakka, Timothy D. Cushing, Oleg Epstein, Brian M. Fox, Stephanie Geuns-Meyer, Xiaolin Hao, Kenta Hibiya, Jun Hirata, Zihao Hua, Jason Human, Shinji Kakuda, Patricia Lopez, Ryota Nakajima, Kazuhisa Okada, Steven H. Olson, Hiroyuki Oono, Lewis D. Pennington, Kosuke Sasaki, Keiko Shimada, Youngsook Shin, Ryan D. White, Ryan P. Wurz, Shuyan Yi, Xiao Mei Zheng
  • Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
    Patent number: 9346798
    Abstract: The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: May 24, 2016
    Assignee: AMGEN INC.
    Inventors: Christiane Boezio, Alessandro Boezio, Howard Bregman, Nagasree Chakka, James R. Coats, Katrina Woodin Copeland, Erin F. Dimauro, Thomas Dineen, Hua Gao, Daniel La, Isaac E. Marx, Hanh Nho Nguyen, Emily Anne Peterson, Matthew Weiss
  • Oxazolidinone compounds and derivatives thereof
    Patent number: 9340549
    Abstract: Compounds of Formula (I) and Formula (II) are useful inhibitors of tankyrase. Compounds of Formula (I) and Formula (II) have the following structure: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: May 17, 2016
    Assignee: AMGEN INC.
    Inventors: Howard Bregman, John L. Buchanan, Nagasree Chakka, Erin F. Dimauro, Hakan Gunaydin, Angel Guzman-Perez, Zihao Hua, Hongbing Huang, Xin Huang, Matthew W. Martin, Vinod F. Patel
  • Carboxamides as inhibitors of voltage-gated sodium channels
    Patent number: 9334269
    Abstract: The present invention provides compounds that are inhibitors of voltage-gated sodium channels (Nav), in particular Nav 1.7, and are therefore useful for the treatment of diseases treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: February 16, 2011
    Date of Patent: May 10, 2016
    Assignee: AMGEN INC.
    Inventors: Howard Bregman, John L. Buchanan, Nagasree Chakka, Erin F. Dimauro, Bingfan Du, Hanh Nho Nguyen, Xiao Mei Zheng
  • SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS
    Publication number: 20150291623
    Abstract: This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
    Type: Application
    Filed: November 14, 2014
    Publication date: October 15, 2015
    Inventors: Mikhail Chafeev, Sultan Chowdhury, Lauren Fraser, Jianmin Fu, Jonathan Langille, Shifeng Liu, Jianyu Sun, Shaoyi Sun, Serguei Sviridov, Mark Wood, Alla Yurevna Zenova, Qi Jia, Jean-Jacques Alexandre Cadieux, Simon J. Gauthier, Amy Frances Douglas, Tom Hsieh, Nagasree Chakka, Zoran Cikojevic
  • Pyrazole Amide Derivative
    Publication number: 20150266824
    Abstract: The present invention relates to a novel compound having a function of inhibiting ROR? activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.
    Type: Application
    Filed: February 27, 2015
    Publication date: September 24, 2015
    Inventors: Hilary Plake Beck, Shon Keith Booker, Howard Bregman, Victor J. Cee, Nagasree Chakka, Timothy D. Cushing, Oleg Epstein, Brian M. Fox, Stephanie Geuns-Meyer, Xiaolin Hao, Kenta Hibiya, Jun Kirata, Zihao Hua, Jason Human, Shinji Kakuda, Patricia Lopez, Ryota Nakajima, Kazuhisa Okada, Steven H. Olson, Hiroyuki Oono, Lewis D. Pennington, Kosuke Sasaki, Keiko Shimada, Youngsook Shin, Ryan D. White, Ryan P. Wurz, Shuyan Yi, Xiao Mei Zheng
  • Quinazolinone Compounds and Derivatives Thereof
    Publication number: 20150225396
    Abstract: Compounds of Formula I are useful inhibitors of tankyrase. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
    Type: Application
    Filed: August 27, 2013
    Publication date: August 13, 2015
    Inventors: Howard Bregman, John L. Buchanan, Nagasree Chakka, Erin F. Dimauro, Hakan Gunaydin, Angel Guzman-Perez, Zihao Hua, Xin Huang
  • N-piperidinyl acetamide derivatives as calcium channel blockers
    Patent number: 9096522
    Abstract: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing N-piperidinyl acetamide derivatives as shown in formula (1).
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: August 4, 2015
    Assignee: Zalicus Pharmaceuticals, Ltd.
    Inventors: Hassan Pajouhesh, Ramesh Kaul, Yanbing Ding, Yongbao Zhu, Lingyun Zhang, Nagasree Chakka, Michael Edward Grimwood, Jason Tan, Yuanxi Zhou
  • Bicyclic aryl and heteroaryl sodium channel inhibitors
    Patent number: 9012443
    Abstract: The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: April 21, 2015
    Assignee: Amgen Inc.
    Inventors: Christiane Boezio, Howard Bregman, James R. Coats, Erin F. Dimauro, Thomas Dineen, Bingfan Du, Russell Graceffa, Charles Kreiman, Daniel La, Isaac E. Marx, Nagasree Chakka, Hanh Nho Nguyen, Emily Anne Peterson, Matthew Weiss, Katrina W. Copeland, Holly L. Deak, Alessandro Boezio
  • DIHYDROBENZOXAZINE AND TETRAHYDROQUINOXALINE SODIUM CHANNEL INHIBITORS
    Publication number: 20150057271
    Abstract: The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Application
    Filed: February 12, 2013
    Publication date: February 26, 2015
    Inventors: Christiane Boezio, Alessandro Boezio, Howard Bregman, Nagasree Chakka, James R. Coats, Katrina Woodin Copeland, Erin F. Dimauro, Thomas Dineen, Hua Gao, Daniel La, Isaac E. Marx, Hanh Nho Nguyen, Emily Anne Peterson, Matthew Weiss